K081927

510(k) Summary

Submitters Name and Address: ReNu Medical, Inc.
9800 Evergreen Way
Everett, WA 98024
Phone: 425-353-1110
Fax: 425-353-9116

FEB - 6 2009

FDA Registration Number: 3034520

Contact Person: L. Bruce Pierson
Chief Operating Officer

Date Summary Prepared:

Trade or Proprietary Name(s): ReNu Medical Reprocessed Oximetry Sensors

Common Name: Oximetry Sensors

Classification: Oximeter (21 CFR 870.2700) / NLF

Equivalent Device(s)

The ReNu Medical Reprocessed Oximetry Sensors are substantially equivalent to the Masimo™ LNCS Adtx, LNCS Pdtx, LNCS Inf and LNCS Neo Oximetry sensors.

Device Description:

The ReNu Medical Reprocessed Masimo™ LNCS probes are accessory devices to an oximeter monitoring system. The oxisensor is designed as a transducer for the transmission of electrical signals from the oximeter to the patient and the return of patient modified signals back to the oximeter for analysis and display of patient information. The sensor contains three optical components; two light emitting diodes (LEDs) serve as light sources and one photodiode acting as a light detector LED and sensor are contained in a laminated envelope provided with an adhesive bandage for attachment a patient. A sensor package is attached to a cable terminated in a multi-pin connector that plugs into the oximeter.

Intended Use

The ReNu Medical Reprocessed Oximetry Sensors are intended as single patient use O_2 transducer/accessory sensors for use in conjunction with the Masimo™ Oximeter system.

The LNCS Adult is used for patients >30 kg.
The LNCS Pediatric is used for patients 10-50 kg.
The LNCS Infant is used for patients 3-20 kg.
The LNCS Neo is used for neonates <3 kg or adults >40 kg.

All sensors are used for non-invasive monitoring of pulse oxygen hemoglobin saturation (SpO_2) and pulse rate.

The predicate devices and the ReNu Medical Reprocessed devices contain identical components (LED, photodiode, laminated envelope, cable, and connector.) The means of patient attachment (adhesive bandage) is identical.

Summary of Comparison Tests

Based on an assessment consisting of bench testing and clinical performance data the ReNu Medical Reprocessed Oximetry Sensors function in a manner that is Substantially Equivalent to that of the predicate devices.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

FEB - 6 2009

Mr. L. Bruce Pierson
Chief Operating Officer
Renu Medical, Incorporated
9800 Evergreen Way
Everett, Washington 98204

Re: K081927
Trade/Device Name: ReNu Reprocessed Masimo Oximeter Sensor Model LNCS Adult, LNCS Pediatric, LNCS Infant, LNCS Neo
Regulation Number: 870.2700
Regulation Name: Oximeter
Regulatory Class: II
Product Code: NLF
Dated: January 26, 2009
Received: January 28, 2009

Dear Mr. Pierson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Ginette Y. Michaud M.D.

Ginette Y. Michaud, M.D.
Acting Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K081927

Device Name: ReNu Reprocessed Masimo Oximeter Sensor Model LNCS Adult, LNCS Pediatric, LNCS Infant, LNCS Neo.

Indications For Use:

The ReNu Medical Reprocessed Oximetry Sensors are intended as single patient use O_2 transducer/accessory sensors for use in conjunction with the Masimo™ Oximeter system.

The LNCS Adult is used for patients >30 kg.
The LNCS Pediatric is used for patients 10-50 kg.
The LNCS Infant is used for patients 3-20 kg.
The LNCS Neo is used for neonates <3 kg or adults >40 kg.

All sensors are used for non-invasive monitoring of pulse oxygen hemoglobin saturation (SpO_2) and pulse rate.

Prescription Use XX AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K081927